Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01394055 · ClinicalTrials.gov registry record · Phase 1

Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

A Phase 1 study of Gastroparesis and Gastrointestinal Motility Disorder, sponsored by Motus Therapeutics.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01394055: Completed Phase 1 study of Gastroparesis and Gastrointestinal Motility Disorder, sponsored by Motus Therapeutics.

NCT01394055 is a Phase 1 study of Gastroparesis and Gastrointestinal Motility Disorder that has completed, run by Motus Therapeutics. The registered enrollment target is 20 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01394055, a Phase 1 study of Gastroparesis and Gastrointestinal Motility Disorder, has completed, sponsored by Motus Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.

Primary Outcome

Change from baseline in gastric half-emptying time by scintigraphy (solids and liquids)

Interventions

  • DRUG Placebo
  • DRUG RM-131

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-07
Est. Completion 2012-12
Phase Phase 1
Motus Therapeutics

7 total trials

What the finished NCT01394055 record still lists

NCT01394055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower).

The record links to 4 conditions, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01394055 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT01394055 about?

NCT01394055 is a clinical study titled "Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis". The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.

What is the current status of trial NCT01394055?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-07. Estimated completion is 2012-12.

What conditions does trial NCT01394055 study?

This clinical trial studies the following conditions: Gastroparesis, Gastrointestinal Motility Disorder, Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications.

What interventions are being tested in trial NCT01394055?

The interventions under investigation include: Placebo (DRUG), RM-131 (DRUG).

Who is sponsoring clinical trial NCT01394055?

This trial is sponsored by Motus Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01394055 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01394055's enrollment target sits among peer trials

20 34th of 44 higher than 9 of 44 other Gastroparesis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01394055, the US trial registry maintained by the National Library of Medicine. NCT01394055 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.